Englander Institute for Precision Medicine

Publications

Found 33 results
Author Title Type [ Year(Asc)]
Filters: Keyword is Urinary Bladder Neoplasms  [Clear All Filters]
2024
Sridhar SS, Powles T, Durán MÁCliment, Park SHoon, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB et al..  2024.  Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.. Eur Urol. 85(2):154-163.
Cicin I, Plimack ER, Gurney H, Leibowitz R, Alekseev BY, Parnis FX, Peer A, Necchi A, Bellmunt J, Nishiyama H et al..  2024.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.. BMC Cancer. 23(Suppl 1):1256.
Ohara K, Rendeiro AFigueiredo, Bhinder B, Eng KWha, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS et al..  2024.  The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.. Nat Commun. 15(1):2009.
Nguyen DD, Hooper WF, Liu W, Chu TR, Geiger H, Shelton JM, Shah M, Goldstein ZR, Winterkorn L, Helland A et al..  2024.  The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.. Nature. 635(8037):219-228.
2023
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
Grivas P, Grande E, Davis ID, Moon HH, Grimm M-O, Gupta S, Barthélémy P, Thibault C, Guenther S, Hanson S et al..  2023.  Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.. ESMO Open. 8(6):102050.
Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, Karkampouna S, Chouvardas P, Genitsch V, Rodriguez-Calero A et al..  2023.  Bladder cancer organoids as a functional system to model different disease stages and therapy response.. Nat Commun. 14(1):2214.
Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, Eng K, Bhinder B, Uppal M, Récapet C et al..  2023.  The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.. Cancer Res. 83(4):506-520.
Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, Lee J-L, van der Heijden MS, Rosenbaum E, Penel N et al..  2023.  FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on / mRNA Expression.. J Clin Oncol. 41(3):629-639.
Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, Huang RSP, Li R, Manley B, Chahoud J et al..  2023.  Immunotherapy in the Treatment of Localized Genitourinary Cancers.. JAMA Oncol. 9(10):1447-1454.
Bamias A, Merseburger A, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabrò F, Kramer M, de Velasco G et al..  2023.  New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.. J Immunother Cancer. 11(1)
Borregales LD, Venkat S, Calderon LPosada, Lewicki P, Flynn T, Faltas BM, Molina AM, Golombos DM, O'Malley P, Scherr DS.  2023.  A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.. Eur Urol. 84(6):604-606.
2022
de Wit R, Powles T, Castellano D, Necchi A, Lee J-L, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN et al..  2022.  Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. Br J Clin Pharmacol. 88(7):3182-3192.
Ertl IE, Lemberger U, Ilijazi D, Hassler MR, Bruchbacher A, Brettner R, Kronabitter H, Gutmann M, Vician P, Zeitler G et al..  2022.  Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.. Eur Urol. 82(3):261-270.
Powles T, Park SHoon, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullén A et al..  2022.  Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.. Future Oncol. 18(19):2361-2371.
van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA et al..  2022.  Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. Nat Commun. 13(1):1878.
Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JLyun, Fléchon A, Roubaud G, Pouessel D, Zagonel V, Calabrò F et al..  2022.  Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. Eur J Cancer. 163:55-65.
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee J-L, Fong L, Necchi A, Sternberg CN, O'Donnell PH et al..  2022.  Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. Clin Cancer Res. 28(10):2050-2060.
Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, Tagawa ST, Molina AM, Sternberg CN, Nanus DM et al..  2022.  Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. Br J Cancer. 126(3):430-439.
Alnajar H, Ravichandran H, Rendeiro AFigueiredo, Ohara K, Zoughbi WAl, Manohar J, Greco N, Sigouros M, Fox J, Muth E et al..  2022.  Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. Cold Spring Harb Mol Case Stud. 8(3)
Yu H, Sfakianos JP, Wang L, Hu Y, Daza J, Galsky MD, Sandhu HS, Elemento O, Faltas BM, Farkas AM et al..  2022.  Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms.. Mol Cancer Ther. 21(11):1729-1741.
2021
Grivas P, Agarwal N, Pal S, Kalebasty ARezazadeh, Sridhar SS, Smith J, Devgan G, Sternberg CN, Bellmunt J.  2021.  Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.. Cancer Treat Rev. 97:102187.
Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJasmine, Ching KA, Pu J, Sternberg CN, Petrylak DP, Tambaro R et al..  2021.  Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.. Nat Med. 27(12):2200-2211.
Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U et al..  2021.  Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.. Oncologist. 26(12):1026-1034.